Zobrazeno 1 - 10
of 100
pro vyhledávání: '"K Lassiter"'
Autor:
Christina D, Mack, Erin B, Wasserman, Deverick J, Anderson, Gabriel, Farkas, Molly, Delaney, Daniel, Eichner, Kyle, Johnston, Madeline K, Lassiter, Emily, Myers, Thom, Mayer, Gary, Solomon, Allen, Sills
Publikováno v:
The Physician and Sportsmedicine. 51:234-239
To quantify levels of potential exposure to SARS-CoV-2 surrounding a typical professional American football game, with a focus on interactions on-field between teammates and opposing players before, during, and immediately after competition.We examin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d942f87b4418168eebb9ccc3346a7dd
https://doi.org/10.1080/00913847.2022.2028536
https://doi.org/10.1080/00913847.2022.2028536
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Daniel P. Petrylak, Lance K. Lassiter, Mohan K. Tummala, Maha Hussain, Michael A. Carducci, Walter M. Stadler
Publikováno v:
Clinical Genitourinary Cancer. 6:31-35
Background Piritrexim is reported to have a response rate of 38% in patients with chemotherapy-naive disease and 23% for second-line therapy after chemotherapy failure. We report the results of a multiinstitutional, open-label, 2-stage, phase II stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f4adf8cd9c4ece1c4223b9e80b2bbf9
https://doi.org/10.3816/cgc.2008.n.005
https://doi.org/10.3816/cgc.2008.n.005
Autor:
Kimberly Dinh, John J. Wright, Deborah K. Armstrong, Michael A. Carducci, Lance K. Lassiter, Ross C. Donehower, Rana Sullivan, Wells A. Messersmith, Virna Almuete, Sharyn D. Baker
Publikováno v:
Clinical Cancer Research. 12:1270-1275
PURPOSE: Bortezomib (PS-341), a first-in-class proteasome inhibitor, is metabolized by deboronation involving cytochrome P4503A (CYP3A), which also metabolizes docetaxel. Preclinical studies have shown synergy between bortezomib and taxanes. We condu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74d444b0865a306707d7f428614fe815
https://doi.org/10.1158/1078-0432.ccr-05-1942
https://doi.org/10.1158/1078-0432.ccr-05-1942
Autor:
Lance K. Lassiter, Michael A. Carducci
Publikováno v:
Seminars in Oncology. 30:678-688
The endothelin (ET) axis represents a novel and exciting target in the treatment of prostate cancer. ET-1, acting primarily through the endothelin A receptor (ET A ), is integrally involved in multiple facets of prostate cancer progression, including
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb95362a888677ad52c7937082fbc79f
https://doi.org/10.1016/s0093-7754(03)00353-1
https://doi.org/10.1016/s0093-7754(03)00353-1
Autor:
Michael A. Carducci, Lance K. Lassiter
Publikováno v:
American Journal of Cancer. 2:181-199
Bone metastases are the most frequent complication of advanced prostate cancer and are responsible for the vast majority of disease-related morbidity and mortality. With the extensive number of predictive models for patients with prostate cancer, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f28ce1d1a520a06a340f1976051a053
https://doi.org/10.2165/00024669-200302030-00003
https://doi.org/10.2165/00024669-200302030-00003
Publikováno v:
Seminars in Urologic Oncology. 20:146-154
Patients with a rising prostate-specific antigen (PSA) levels after definitive local therapy now represent one of the largest and fastest growing groups of men with prostate cancer. The great majority of these men are asymptomatic with no other evide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::374ca030329d91aede0cf37c658b8295
https://doi.org/10.1053/suro.2002.32834
https://doi.org/10.1053/suro.2002.32834